Implementation of support tools to promote safety in the prescribing of oral contraceptives

实施支持工具以促进口服避孕药处方的安全性

• 批准号: 10547335
• 负责人: Mary Kucek
• 金额: $ 21.47万
• 依托单位: OVARYIT, LLC
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-05 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10547335
• 关键词: Address; Adoption; Affect; Birth Intervals; Businesses; Caring; Child; Clinical; Contraceptive Agents; Counseling; Data; District of Columbia; Documentation; Economics; Education; Electronic Health Record; Expenditure; Family; Financial Hardship; Florida; Focus Groups; Foundations; Gender; Government; Growth; Guidelines; Health; Health Benefit; Health Insurance Portability and Accountability Act; Health Personnel; Health Services Accessibility; Health system; Incentives; Leadership; Maternal Mortality; Medicaid; Medical; Medical Technology; Medicine; Mental Health; Minority Women; Mothers; Needs Assessment; Oral Contraceptives; Outcome; Pain; Paper; Patients; Persons; Pharmacists; Pharmacy facility; Phase; Policies; Pregnancy; Privatization; Process; Quality of life; Reproductive Health; Risk; Safety; Services; Societies; Standardization; Surveys; System; Time; Training; Transportation; United States; Woman; base; clinical decision support; commercialization; cost; cost effective; design; empowered; health care availability; hormonal contraception; interest; low socioeconomic status; maternal morbidity; minority children; payment; physical conditioning; point of care; prevent; social; success; support tools; telehealth; tool; unintended pregnancy

Summary Nearly half of the pregnancies in the United States are unintended despite the discovery of the first combination hormonal contraceptive in the 1960s. Hormonal contraceptives are an efficacious and cost-effective strategy to decrease the rate of unintended pregnancy. Lack of access to contraceptive services, especially for adolescents, minority women, and women of lower socioeconomic status creates significant health and financial inequities and leads to significant US government expenditures. Pharmacist-prescribed contraceptive services have the potential to increase access to care, decreasing the number of unintended pregnancies in the US. Pharmacists have expressed interest in providing contraceptive services but have cited several barriers that currently serve to hinder their expansion. For the widespread growth of pharmacist-prescribed contraceptive services, an implementation package is needed that addresses the barriers that currently exist. A contraceptive-specific Electronic Health Record system that increases efficiency, incorporates point-of-care tools, and is affordable will be the foundation of a successful implementation package. OvaryIt, a Florida-based small business, has developed a proprietary HIPAA-compliant contraceptive-specific platform for the provision of direct-to-consumer telehealth services. We propose to adapt this platform to serve as the foundation of a comprehensive implementation package to expand in-person pharmacist-prescribed contraceptive services. Phase I will support studies to investigate the feasibility and establish a proof-of-concept of such a solution. Aim 1: Conduct a needs assessment to determine operational requirements. This will result in project documentation and the roadmap needed to integrate contraceptive functionality within existing Pharmacy Management Systems. Aim 2: Completion of a study of 20 pharmacist end-users comparing the OvaryIt platform to the current standard paper charting process. Each pharmacist will complete two standardized contraceptive patient encounters, one utilizing each process. Outcomes will include time to completion of the encounter, compliance with the USMEC guidelines, appropriate prescription selection, and quantitative survey data. Aim 3: Conduct a focus group with pharmacist end-users and administrative stakeholders to discuss the perceived strength and quality of the proposed project solutions for each of the identified barriers or pain points to implementation success. At the end of Phase I, OvaryIt, LLC will have a roadmap for a comprehensive implementation package with vetted solutions for the many barriers that currently prevent the adoption of pharmacist-prescribed contraceptive services. Phase II efforts will allow for the creation of a comprehensive implementation package ready for widespread commercialization to independent, large chain, and health system-based pharmacies. A tremendous market opportunity exists for OvaryIt, LLC and participating pharmacies to create new revenue opportunities while significantly expanding access to contraceptives in the US.

总结 尽管发现了第一个组合，但美国近一半的怀孕是意外的 1960年代的荷尔蒙避孕药激素避孕药是一种有效和具有成本效益的策略， 降低意外怀孕率。缺乏获得避孕服务的机会，尤其是对青少年而言， 少数民族妇女和社会经济地位较低的妇女造成了严重的健康和经济不平等 并导致美国政府大量支出。药剂师处方的避孕服务有 增加获得医疗服务的可能性，减少美国意外怀孕的数量。药剂师 表示有兴趣提供避孕服务，但列举了目前存在的几个障碍， 阻碍他们的扩张。对于药剂师处方避孕服务的广泛增长， 需要采取一揽子执行措施，消除目前存在的障碍。避孕药专用 电子健康记录系统提高了效率，结合了即时护理工具，并且价格实惠， 是成功实施一揽子计划的基础。OvaryIt是一家位于佛罗里达州的小企业， 开发了一个专有的符合HIPAA的避孕专用平台， 远程保健服务。我们建议调整这一平台，以作为一个全面的 实施一揽子计划，以扩大由药剂师亲自处方的避孕服务。第一阶段将支持 研究调查这种解决方案的可行性并建立概念验证。目标1：引导需求 评估以确定业务需求。这将导致项目文档和路线图 需要将避孕功能纳入现有的药房管理系统。目标二： 完成了一项由20名药剂师最终用户参与的研究，将OvaryIt平台与当前的标准论文进行了比较 制图过程每位药剂师将完成两次标准化的避孕患者接触，一次使用 每个过程。结果将包括完成相遇的时间，遵守USMEC 指南、适当的处方选择和定量调查数据。目标3：举办焦点小组会议， 药剂师最终用户和行政利益相关者讨论的感知强度和质量的 针对每个已确定的阻碍成功实施的障碍或痛点提出项目解决方案。年底 在第一阶段，OvaryIt，LLC将有一个经过审查的解决方案的全面实施包的路线图 因为目前有许多障碍阻止采用药剂师处方的避孕服务。相 II的努力将有助于创建一个全面的实施包，为广泛使用做好准备 商业化的独立，大型连锁店，和卫生系统为基础的药店。巨大的市场 OvaryIt，LLC和参与药店有机会创造新的收入机会， 在美国大大增加了避孕药具的使用。